Hylly
Henkilönnimi Stief, Marco, kirjoittaja.
Nimeke- ja vastuullisuusmerkintö Do the experimental use and bolar exemptions also apply in contributory patent infringement cases?
Julkaistu Oxford University Press, Oxford : 2022.
Ulkoasutiedot
Sarjamerkintö ei-lisäkirjausmuodossa Journal of Intellectual Property Law & Practice, ISSN 1747-1532 ; 17(8)
Huomautus sisällöstä, tiivistelmä tms. The reach of § 10(3) of the German Patent Act (GPA) has been the subject of debate by the German patent courts and other interested circles for many years. Clarification by the German Supreme Court is still awaited on the extent to which third parties are liable for their own supplying acts which do not themselves fall under one of the privileged provisions of § 11 Nos. 1 to 3 GPA. This poses considerable legal risks for both suppliers and recipients, which are particularly evident in the pharmaceutical sector in the context of privileged acts covered by § 11 No. 2 or No. 2b GPA. The authors explore the history of the legal provision, examine the approaches taken in the German literature and case law to date and discuss possible contractual and practical measures to reduce the liability risk.
Asiasana
Maantieteellinen nimi asiasanana
Henkilönnimi Matschke, Tobias, kirjoittaja.
Sarjalisäkirjaus - yhtenäistetty nimeke Journal of Intellectual Property Law & Practice, 1747-1532 ; 17(8)
*000 ab a ar
*00117477
*008 s2022||||xxk|||||||||||||||||eng||
*040 $aFI-CUTE$bfin$erda
*0410 $aeng
*1001 $aStief, Marco,$ekirjoittaja.
*24510$aDo the experimental use and bolar exemptions also apply in contributory patent infringement cases? /$cMarco Stief, Tobias Matschke.
*264 1$aOxford :$bOxford University Press,$c2022.
*300 $as. 629–639
*336 $ateksti$btxt$2rdacontent
*337 $akäytettävissä ilman laitetta$bn$2rdamedia
*338 $anide$bnc$2rdacarrier
*4901 $aJournal of Intellectual Property Law & Practice,$x1747-1532 ;$v17(8)
*520 $aThe reach of § 10(3) of the German Patent Act (GPA) has been the subject of debate by the German patent courts and other interested circles for many years. Clarification by the German Supreme Court is still awaited on the extent to which third parties are liable for their own supplying acts which do not themselves fall under one of the privileged provisions of § 11 Nos. 1 to 3 GPA. This poses considerable legal risks for both suppliers and recipients, which are particularly evident in the pharmaceutical sector in the context of privileged acts covered by § 11 No. 2 or No. 2b GPA. The authors explore the history of the legal provision, examine the approaches taken in the German literature and case law to date and discuss possible contractual and practical measures to reduce the liability risk.
*650 7$ateollisoikeus$2yso/fin$0http://www.yso.fi/onto/yso/p3067
*650 7$apatenttijärjestelmät $0http://www.yso.fi/onto/yso/p21185$2yso/fin
*650 7$apatentit$0http://www.yso.fi/onto/yso/p3069$2yso/fin
*650 7$apatentointi$2yso/fin$0http://www.yso.fi/onto/yso/p11913
*651 7$aSaksa$0http://www.yso.fi/onto/yso/p105087$2yso/fin
*7001 $aMatschke, Tobias,$ekirjoittaja.
*830 0$aJournal of Intellectual Property Law & Practice,$x1747-1532 ;$v17(8)
*852 $hSA-JIPLP
^
Tästä teoksesta ei ole arvioita.
Näpäytä
kun haluat kirjoittaa ensimmäisen arvion.